{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:16:34Z","timestamp":1778544994683,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["MCL7001-18"],"award-info":[{"award-number":["MCL7001-18"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["\/NCI RO1CA18894"],"award-info":[{"award-number":["\/NCI RO1CA18894"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hoc.2020.05.003","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T13:02:04Z","timestamp":1596286924000},"page":"809-823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cell Cycle Dysregulation in Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Kevin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Di Liberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina","family":"Chen-Kiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2020.05.003_bib1","first-page":"1437","article-title":"Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster","volume":"7","author":"Williams","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.05.003_bib2","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V84.8.2726.2726","article-title":"PRAD-1\/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma","volume":"84","author":"Bosch","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib3","first-page":"1833","article-title":"Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma","volume":"10","author":"de Boer","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2020.05.003_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/(SICI)1096-9896(199607)179:3<238::AID-PATH566>3.0.CO;2-W","article-title":"bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma","volume":"179","author":"Ott","year":"1996","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.hoc.2020.05.003_bib5","doi-asserted-by":"crossref","first-page":"9638","DOI":"10.1073\/pnas.88.21.9638","article-title":"PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma","volume":"88","author":"Rosenberg","year":"1991","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2020.05.003_bib6","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2010-06-288027","article-title":"Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors","volume":"117","author":"Bretz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","article-title":"The broken cycle: E2F dysfunction in cancer","volume":"19","author":"Kent","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hoc.2020.05.003_bib8","first-page":"4608","article-title":"Alterations of the cyclin D1\/p16-pRB pathway in mantle cell lymphoma","volume":"57","author":"Dreyling","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2020.05.003_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2020.05.003_bib10","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib11","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2006-08-039859","article-title":"Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival","volume":"109","author":"Wiestner","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib12","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","article-title":"Genomic landscape and prognostic analysis of mantle cell lymphoma","volume":"25","author":"Yang","year":"2018","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.hoc.2020.05.003_bib14","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib15","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2013-01-478834","article-title":"The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma","volume":"121","author":"Meissner","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib16","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib17","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2020.05.003_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2020.05.003_bib19","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2018-07-862151","article-title":"CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1(-) mantle cell lymphoma","volume":"133","author":"Martin-Garcia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib20","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/0008-5472.CAN-04-1526","article-title":"CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a\/ARF locus","volume":"65","author":"Hernandez","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2020.05.003_bib21","first-page":"4365","article-title":"Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants","volume":"93","author":"Bea","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib22","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2020.05.003_bib23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V89.1.272","article-title":"Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas","volume":"89","author":"Pinyol","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib24","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fernandez","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2020.05.003_bib25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","article-title":"A\u00a0gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome","volume":"132","author":"Clot","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib27","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1182\/blood-2006-11-057208","article-title":"Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis","volume":"109","author":"Pinyol","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ijc.21370","article-title":"Analysis of Aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma","volume":"118","author":"Camacho","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hoc.2020.05.003_bib29","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2020.05.003_bib30","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1073\/pnas.050400997","article-title":"Mantle cell lymphoma is characterized by inactivation of the ATM gene","volume":"97","author":"Schaffner","year":"2000","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2020.05.003_bib31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V99.1.238","article-title":"ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances","volume":"99","author":"Camacho","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3324\/haematol.10891","article-title":"Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309","volume":"92","author":"Hartmann","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.05.003_bib33","first-page":"155","article-title":"Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature","volume":"6","author":"Setoodeh","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.hoc.2020.05.003_bib34","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1080\/10428190410001711479","article-title":"Burkitt transformation of mantle cell lymphoma","volume":"45","author":"Felten","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2020.05.003_bib35","first-page":"1225","article-title":"8q24 translocations in blastic transformation of mantle cell lymphoma","volume":"85","author":"Au","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.05.003_bib36","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.05.003_bib37","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1158\/1078-0432.CCR-08-3215","article-title":"Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma","volume":"15","author":"Psyrri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2020.05.003_bib38","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts","volume":"3","author":"Fry","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.hoc.2020.05.003_bib39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","article-title":"Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine","volume":"32","author":"Gelbert","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.hoc.2020.05.003_bib40","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.1158\/1078-0432.CCR-13-1675","article-title":"Dual CDK4\/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma","volume":"19","author":"Rader","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2020.05.003_bib41","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","article-title":"A\u00a0novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6","volume":"66","author":"Baughn","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2020.05.003_bib42","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1182\/blood-2006-04-016634","article-title":"Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity","volume":"108","author":"Marzec","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib43","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2007-02-071266","article-title":"Pharmacologic inhibition of CDK4\/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia","volume":"110","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib44","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in\u00a0vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.hoc.2020.05.003_bib45","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/0008-5472.CAN-07-6404","article-title":"A\u00a0novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model","volume":"68","author":"Menu","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2020.05.003_bib46","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccr.2012.09.016","article-title":"Therapeutic targeting of the cyclin D3:CDK4\/6 complex in T\u00a0cell leukemia","volume":"22","author":"Sawai","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2020.05.003_bib47","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2012-03-415984","article-title":"Prolonged early G(1) arrest by selective CDK4\/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4","volume":"120","author":"Huang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib48","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/cc.24928","article-title":"Induction of prolonged early G1 arrest by CDK4\/CDK6 inhibition reprograms lymphoma cells for durable PI3Kdelta inhibition through PIK3IP1","volume":"12","author":"Chiron","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.hoc.2020.05.003_bib49","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib50","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2019.1612062","article-title":"A\u00a0phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma","author":"Martin","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2020.05.003_bib51","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A\u00a0phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma","volume":"133","author":"Martin","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.05.003_bib53","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib54","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.05.003_bib55","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1182\/blood.V124.21.3067.3067","article-title":"Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma","volume":"124","author":"Morschhauser","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.05.003_bib56","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-1248","article-title":"A\u00a0phase I study of the cyclin-dependent kinase 4\/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas","volume":"22","author":"Infante","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2020.05.003_bib57","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1080\/10428194.2016.1239259","article-title":"The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group","volume":"58","author":"Seftel","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2020.05.003_bib58","doi-asserted-by":"crossref","first-page":"18007","DOI":"10.1038\/s41598-017-18368-w","article-title":"Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition","volume":"7","author":"Dey","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.hoc.2020.05.003_bib59","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2020.05.003_bib60","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2020.05.003_bib61","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A\u00a0cancer cell program promotes T\u00a0cell exclusion and resistance to checkpoint blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:59:18Z","timestamp":1778543958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0889858820300630"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.05.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell Cycle Dysregulation in Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}